

Care Optimisation in COPD Service.

GlaxoSmithKline (UK Ltd) and NHS Borders Health Board.

Executive Summary

Author: Kerry Straughan (GSK Respiratory Partnership Manager) and Andy Currie (Regional Account Manager). This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

NHS Borders Health Board and GSK are undertaking a Joint Working project with the aim of care optimisation in COPD. This involves a balance of contributions with the pooling of skills, experience and resources. The project aims to compliment existing NHS service provision to provide equity of care and service for patients with COPD. Overall, the programme aims to:

- Provide patients with equity of care by ensuring patients are managed according to clinical need and current local guidelines
- Reduce practice burden of long-term condition management through provision of clinical pharmacist resource
- Which leads to sustained improvement in quality of primary care COPD management:
 - education and upskilling of healthcare professionals
 - Quality Improvement (QI) platform to support the prioritisation of ongoing workstreams
- Improve COPD outcomes and expected reduction in non-elective hospital admissions through optimisation of COPD management.

The project will run from April 2021- April 2022.

Key Objectives:

- Increase in number of appropriate patients who have a recorded COPD annual review.
- Increased formulary compliance in COPD across health board
- Increased use of CAT/MRC across Borders health board.
- Through the successful delivery of the project demonstrate the value of collaboration between the NHS and GSK.
- Reduce healthcare utilisation as demonstrated by reduced emergency GP attendances and Emergency Department attendances.
- Education delivery for health care professionals within Borders Health Board.

Intended Benefits:

Patients	<ul style="list-style-type: none">• Fewer COPD-related hospital admissions• Better informed about COPD management and treatment options• COPD managed in accordance with current best practice clinical guidance• Better experience of the healthcare system – access to a clinical pharmacist and/or upskilled primary care clinician at their own GP practice
NHS	<ul style="list-style-type: none">• Services are configured around patient and local healthcare economy needs – programme modules have been selected to complement existing services and/or meet any gaps in existing care provision

	<ul style="list-style-type: none"> • Insight into COPD population at practice and local healthcare economy level to allow benchmarking and evaluation of care provision to support clinical governance and support equity of care • Provision of clinical pharmacist resource allows practice clinical staff to be redeployed to focus on other workstreams • Opportunity to upskill primary care clinicians • Better health outcomes for the COPD patient population • Reduction in COPD-related hospital admissions
GSK	<ul style="list-style-type: none"> • Faster implementation of NHS Borders policy relating to COPD care provision • Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme • Increase in the appropriate use of medicines licensed for COPD aligned to local or national guidance, with likely increase in the prescribing of GSK products as well as those of other pharmaceutical companies. • Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care • Helps GSK to live its values in being a patient focussed company.